Skip to main content
Clinical Trials/JPRN-jRCT1080222828
JPRN-jRCT1080222828
Unknown
未知

A multicenter, longitudinal, non-drug study to assess the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in Japanese individuals with Down syndrome aged 6-30.

Chugai Pharmaceutical Co., Ltd.0 sites40 target enrollmentApril 15, 2015
ConditionsDown Syndrome

Overview

Phase
未知
Intervention
Not specified
Conditions
Down Syndrome
Sponsor
Chugai Pharmaceutical Co., Ltd.
Enrollment
40
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 15, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \*Subjects with diagnosis of Down Syndrome.Subjects may have standard trisomy 21, Robertsonian translocation, isochromosome21,Down syndrome with reciprocal translocation or mosaicism.
  • \*Availability of parent or other reliable caregiver who agrees to accompany the subject to clinic visits, provide information about the subject's behavior and symptoms.
  • \*Down Syndrome subjects meeting clinical diagnostic criteria for generalized anxiety disorders, major depressive disorders, autism spectrum disorder, attention deficit and hyperactivity disorder, can participate to the study provided they are on stable medication for at least 8 weeks prior to screening.

Exclusion Criteria

  • Individuals who may not be able to comply with the protocol or perform the outcome measures due to significant hearing or visual impairment or other issues judged relevant by the investigators.

Outcomes

Primary Outcomes

Not specified

Similar Trials